Because it is noncytotoxic and generally well tolerated with minimal drug interactions, use of enasidenib in combination with other AML treatments may prove beneficial and is under investigation in patients with newly diagnosed mutant-IDH2 AML in combination with azacitidine (ClinicalTrials.govNCT02677922), and in combination with standard induction chemotherapy (ClinicalTrials.govNCT02632708). This evidence concerns the gene IDH2 and acute myeloid leukemia.